## Definition
The Healthcare Common Procedure Coding System (HCPCS) code J9340 refers to durvalumab, a monoclonal antibody used as an immunotherapy agent in the treatment of certain cancers. Specifically, it describes a dosage of 10 milligrams of durvalumab administered through injection, typically in a clinical or hospital outpatient setting. This code is designated for billing and reimbursement purposes within the healthcare system to standardize the reporting of this specific treatment.
Durvalumab operates as a programmed death-ligand 1 (PD-L1) inhibitor, helping the immune system target and eliminate cancer cells more effectively. It is approved by the Food and Drug Administration for the treatment of patients with specific forms of non-small cell lung cancer and advanced urothelial carcinoma. Use of durvalumab involves careful clinical assessment to ensure the appropriate indication and safe administration.
The J9340 code is used by healthcare providers, pharmacies, and facilities involved in the handling and administration of the drug. Correct billing using J9340 is integral to minimizing errors in medical claims and ensuring timely reimbursement from Medicare or commercial insurers. The use of this code is often accompanied by additional codes that denote visit types, administration methods, or modifiers.
—
## Clinical Context
Durvalumab is prescribed within the clinical context of cancer immunotherapy, a rapidly advancing field in oncology. It is indicated for adults with locally advanced or metastatic cancers, particularly when disease progression has occurred following prior treatments. Treatment regimens involving durvalumab are often multidisciplinary, incorporating oncologists, nursing staff, and pharmacists.
Clinicians usually administer durvalumab in intravenous infusion form, and its dosing depends on patient weight and condition. Administration typically occurs once every two or four weeks, depending on the specific treatment protocol. Clinical guidelines specify its use only for approved indications, emphasizing the need for precise oncological assessment and patient monitoring.
Patients receiving durvalumab require regular evaluation to balance therapeutic efficacy and manage potential immune-related adverse effects. These effects may include pneumonitis, colitis, hepatitis, or endocrinopathies, necessitating a proactive approach to toxicity management. Clinicians often adhere to established guidelines, such as those provided by the National Comprehensive Cancer Network.
—
## Common Modifiers
The HCPCS code J9340 is frequently accompanied by modifiers to provide additional details about the billing claim. For instance, modifier JW is used when reporting discarded portions of a single-use vial of durvalumab. This modifier is important for compliance with pharmaceutical waste reporting requirements.
Other modifiers, such as 25 or 59, may be appended to distinguish durvalumab administration when billed alongside other procedures or services performed on the same date of service. Modifier 25 is used to identify a significant, separately identifiable evaluation and management service. Modifier 59, meanwhile, clarifies that distinct procedures or services were rendered during the same visit.
Geographic pricing modifiers may also apply in certain billing scenarios to reflect regional differences in healthcare costs. These modifiers help align reimbursement rates with local market conditions. Proper use of modifiers ensures that claims are processed accurately and minimizes the likelihood of denials.
—
## Documentation Requirements
Proper documentation is vital when billing HCPCS code J9340, as it provides the basis for reimbursement and legal compliance. Clinicians must document the specific diagnosis for which durvalumab is prescribed and indicate how the treatment aligns with FDA-approved or clinically accepted indications. This includes thorough justification for the medical necessity of its use.
Supporting documentation must also include the exact dosage administered and the method of administration. Providers should record the drug’s National Drug Code for reference, as well as the name of the manufacturer if required by the payer. In cases where only part of a vial is used, clinicians should document the discarded portion for compliance with waste reporting.
Finally, documentation must include details about any evaluations or imaging conducted alongside durvalumab administration. These details should correlate with clinical notes that establish the course and progress of treatment. Accurate, comprehensive documentation is critical for claims processing and serves as evidence in the event of audits or payer inquiries.
—
## Common Denial Reasons
Claims submitted with HCPCS code J9340 may be denied for various reasons, many of which stem from documentation or coding errors. One frequent reason for denial is a lack of evidence supporting medical necessity, such as missing or incomplete documentation of the patient’s diagnosis. Payers may also deny claims if the use of durvalumab does not align with FDA-approved indications.
Incorrect or omitted modifiers are another common cause for denials. For instance, failure to include modifier JW for discarded portions of a vial can result in claim denials or underpayment. Similarly, incompatible or nonspecific diagnosis codes used in conjunction with J9340 may lead to claim rejections.
Denials may also occur if claims are submitted with inaccurate dosage information or if the billing quantity does not correlate with the drug’s packaging. Providers must ensure that the dosage, as reported in milligrams, aligns precisely with the quantity administered. Finally, claims can face rejection if prior authorization, when required, has not been obtained.
—
## Special Considerations for Commercial Insurers
Reimbursement policies for HCPCS code J9340 vary significantly among commercial insurance providers. Some commercial insurers may require prior authorization before covering treatments that involve durvalumab. This process typically involves submitting clinical records that verify the drug’s necessity and appropriateness for the patient’s condition.
Commercial insurers may also impose limitations on the frequency or duration of durvalumab treatment. Coverage policies might stipulate that the drug will only be reimbursed after the failure of less costly treatment alternatives. As such, providers must remain informed of specific payer guidelines to avoid claim denials and ensure uninterrupted patient care.
Patients insured through commercial plans may face higher out-of-pocket costs compared to those covered by Medicare, owing to copayment structures and deductibles. Providers should communicate transparently with patients regarding expected financial responsibilities. Clinical offices often collaborate with patient assistance programs sponsored by the drug manufacturer to reduce financial burdens.
—
## Similar Codes
Several other HCPCS codes resemble J9340 in that they are used to describe cancer immunotherapy agents. For example, code J9264 represents paclitaxel protein-bound particles, a chemotherapy agent used for treating cancers such as breast and lung cancer. Although distinct from immunotherapy, it is often billed alongside immune-based treatments in multidisciplinary regimens.
Another commonly used code is J9022, which describes alemtuzumab, a monoclonal antibody for treating B-cell chronic lymphocytic leukemia and multiple sclerosis. Like J9340, J9022 requires precise documentation to substantiate its administration and medical necessity. Both codes share similarities in their use of modifiers and reporting requirements.
Meanwhile, J9271 refers to pembrolizumab, another PD-1 blocking antibody often compared to durvalumab in terms of mechanism and application. While both drugs act on similar immunological pathways, their approved indications and dosing protocols differ. Familiarity with these related codes enables providers to bill accurately based on the treatment delivered.